05/31/2026
After a pancreatic cancer diagnosis put his retirement travel plans on hold, Steve Wallace did not know if he would get the chance to return to the adventures he and his wife had planned. Today, he is preparing for a Caribbean cruise after participating in a clinical trial of daraxonrasib at UT MD Anderson.
Results from the phase 3 study, presented today at the 2026 ASCO Annual Meeting, showed the RAS(ON) inhibitor doubled survival compared with chemotherapy in previously treated pancreatic cancer.
“This is what makes these advances so meaningful,” says our Dr. Shubham Pant. “We are seeing patients regain quality of life and get back to the activities they enjoy.”
Read Steve’s story: http://spr.ly/6188B8gUMp
Daraxonrasib improved symptoms enough that some patients could resume activities they had previously abandoned and a new benchmark for treating the deadly cancer.